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This is the report of a workshop organised by the European Cen-
tre for the Validation of Alternative Methods (ECVAM). ECVAM’s
main goal, as defined in 1993 by its Scientific Advisory Commit-
tee, is to promote the scientific and regulatory acceptance of al-
ternative methods that are of importance to the biosciences and
which replace, reduce or refine the use of laboratory animals. One
of the first priorities set by ECVAM was the implementation of
procedures that would enable it to become well informed about the
state-of-the-art of non-animal test development and validation, and
the potential for the possible incorporation of alternative tests into
regulatory procedures.
It was decided that this would be best achieved by the organiza-
tion of ECVAM workshops on specific topics, at which small groups
of invited experts would review the current status of various types
of in vitro tests and their potential uses, and make recommendations
about the best ways forward (Anonymous, 1994).
The workshop on “The use of in vitro systems for evaluating
Immunotoxicity” was held at ECVAM (Ispra), Italy, on 24th–26th
November 2003. The participants represented academia, national
organizations, international regulatory bodies and industry. The
aim of the workshop was to review the state-of-the-art in the field
of in vitro immunotoxicology, and to develop strategies towards the
replacement of in vivo testing. At the end of this report are listed the
recommendations that should be considered for prevalidation and
validation of relevant and reliable procedures, that could replace
the use of animals in chemical and cosmetics toxicity testing.
Keywords in vitro, methods, immunosuppression, alternative models
INTRODUCTION
The immune system is designed to protect the host against in-
vasive microorganisms such as bacteria and viruses, and against
malignant cells in order to maintain homeostasis. Protection is
provided when the immune system is able to recognize, iso-
late, destroy, and eliminate any intruding parasite. Surveillance,
which is part of the protection mechanisms, implies the recog-
nition and destruction of malignant or otherwise abnormal cells
such as those affected by viruses or chemicals. The capacity of
the immune system to recognize these abnormal cells plays a
crucial role in the prevention of neoplastic diseases (Janeway
and Medzhitov, 2002).
Inherent to the function of the immune organ system is that it
is very diffuse, spread widely over peripheral (immune) organs
and particularly present at sites that are exposed to the outside,
such as mucosa of lungs, intestine, and skin. Development of im-
mune cells takes mainly place in the bone marrow harbouring
pluripotent haematopoietic stem cells, from which all leukocytes
originate. During the first steps of the differentiation process, a
myeloid and a lymphoid stem cell emerge. Subsequent differen-
tiation into lymphocytes of the T- and B-lineages occurs within
the microenvironment of lymphoid organs. T-Cell precursors
pass through the thymus, where they express the antigen recep-
tor and undergo selection.
At least two specific additional properties make the immune
system vulnerable to chemical or physical insults: 1) the immune
system develops rather late in life (thymus development lasts
at least until puberty), and some bone marrow-dependent im-
mune components are continuously renewed (e.g., polymorpho-
nuclear granulocytes) and 2) each parasitic insult, as well as
immune surveillance (including destruction of tumor cells), de-
mands a delicate control of the balance between activation, si-
lencing and regulation of immune reactivity.
Immune responses are the result of an effective collaboration
between innate (natural and relatively nonspecific) and acquired
(adaptive, and extremely specific and modifiable) components of
the immune system. It is now well accepted that innate immune
cells include antigen presenting cells (APC), such as dendritic
cells (DC), sense danger- or pathogen-associated molecular pat-
terns (PAMP), and that recognition of these patterns results in
up-regulation of costimulatory help signals (including receptor
bound molecules, as well as soluble factors like cytokines). To
become activated, T-lymphocytes require costimulatory signals
in addition to recognition of antigen determinants, in the context
of the antigen presenting molecules of the major histocompati-
bility complex (MHC).
It is also accepted that T-cells, in particular T-helper cells,
may develop in either T-helper 1 cells or T-helper 2 cells. By
doing so, T-helper cells orchestrate the ensuing immune re-
sponse by the mixture of cytokines they produce. T-helper 1
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cells stimulate macrophages and/or cytotoxic T-cells to kill and
destroy infected or malignant cells, or to raise a delayed-type
hypersensitivity (DTH) reaction; T-helper 2 cells trigger B-cells
to initiate antibody production.
Being a very aggressive system, control mechanisms have
developed including central tolerance mechanisms (e.g., T-cell
selection in the thymus), requirement of second or costimulatory
signal (absence of costimulation results in silent state of lym-
phocytes), and a range of regulatory mechanisms (regulatory
DC, and T-cells).
HUMAN CLINICAL ADVERSE EFFECTS
Based on the available clinical experience, immunotoxic ef-
fects are best divided into four categories: immunosuppression,
immunostimulation, hypersensitivity, and autoimmunity. Each
category is associated with relatively specific and clinically dis-
tinct adverse events (Descotes, 2004a).
Immunosuppression
Two major types of clinical adverse effects have been identi-
fied in relation to immunosuppression:
Impaired Resistance Against Microbial Pathogens. Pri-
mary (congenital) or secondary (acquired) immune defects are
associated with microbial infections that are more frequent and
more severe, and sometimes atypical, i.e., opportunistic infec-
tions that normally do not develop in immunocompetent indi-
viduals. Infectious complications have often been described in
patients treated with corticosteroids (Klein et al., 2001), radi-
ation or immunosuppressive drugs in the post-transplantation
period (Sia and Paya, 1998; Sleijffers et al., 2002). The possible
occurrence of infectious diseases has not been extensively stud-
ied in humans exposed to occupational or environmental chem-
icals that are immunosuppressive in animals. However, there is
a seemingly similar trend toward more frequent, even though
often clinically unremarkable infections in exposed human be-
ings. For example, contamination of rice oil by a mixture of
polychlorinated biphenyls (PCBs) caused unusual clinical signs
and symptoms—the Yusho or Yu-Cheng disease—and respi-
ratory infections were seen in some patients and were corre-
lated with decreased immune function parameters (Lu¨, 1985;
Nakanishi et al., 1985). Recently, a higher prevalence of recur-
rent inner ear infections has been reported in Dutch preschool
children exposed to PCBs and dioxins (Weisglas-Kuperus et al.,
2004). Inuit infants exposed to organochlorine pesticides were
found to be at a greater risk of developing otitis media (Dewailly
et al., 2000). UV exposure, which is immunosuppressive, is as-
sociated with more frequent infections in man (Termorshuizen
et al., 2002).
No single pathogen is specifically involved in infectious com-
plications associated with immunosuppression, since bacterial,
viral, fungal, and parasitic infections can be seen. Infections of
the respiratory and gastrointestinal tracts are the most frequent,
but skin infections and opportunistic infections of the central
nervous system are also common.
Immunosuppression and Malignancies. Immunocompro-
mised patients, such as those with congenital immune defects
or with the HIV immunodeficiency syndrome, are at a greater
risk of developing virus-related malignancies. Organ transplant
patients treated with long-term immunosuppressive regimens
also develop more frequent malignancies (Vial and Descotes,
2003). Approximately 1% of cancer patients have been re-
ported to develop a second cancer within 10 years after com-
pletion of chemotherapy, and 3% within 20 years. The most
common malignancies in organ transplant recipients are can-
cers of the skin and lips (Wilson, 2003). Many epidemiologi-
cal studies showed that lymphoproliferative disorders are 30-
to 50-fold more frequent in renal transplant patients than in the
general population. The most comprehensive data are those of
the Cincinnati Transplant Tumor Registry (Penn, 1995). Ma-
lignancies are more frequent irrespective of the immunosup-
pressive drugs, though the actual figures do depend on the type
of immunosuppressive therapy. Ionising radiation and alkylat-
ing agents are mutagenic. However, immunosuppressive treat-
ments that are not mutagenic also increase the risk of developing
cancer.
Immunostimulation
The clinical adverse effects related to immunostimulation
in human beings have not yet been extensively investigated.
However, the clinical experience is growing rapidly (Vial and
Descotes, 1995; Vial et al., 2002).
1. Flu-like Reactions: Hyperthermic reactions (>38–38.5◦C)
with chills, arthralgias and malaise have been described in
patients treated with immunostimulatory medicinal products
or following the administration of vaccines. Similar, but more
severe and sometimes treatment-limiting reactions have been
reported in patients treated with recombinant cytokines. Hy-
perthermia can reach 40◦C or more, and is associated with
diarrhea, vomiting, chest pain, hypotension (possibly lead-
ing to cardiovascular collapse or cardiac ischemia), and neu-
rological disorders such as tremor, confusion, obnubilation,
and seizures. The terms “acute cytokine syndrome” and “cy-
tokine release syndrome” tend to be used instead of flu-like
reaction to describe these severe adverse events.
2. Increased Incidence of Autoimmune Diseases: One of the
most frequent immune-mediated adverse effect of some, but
not all recombinant cytokines, is a marked increase in the
incidence of autoimmune diseases (Miossec, 1997). A num-
ber of treated patients developed extremely varied autoim-
mune diseases including auto-immune thyroiditis, thrombo-
cytopenia, hemolytic anemia and hepatitis, systemic lupus
erythematosus, insulin-dependent diabetes mellitus, myas-
thenia gravis, multiple sclerosis, and Sjo¨gren’s syndrome.
Autoimmune thyroiditis is by far the most common finding.
3. Increased Incidence of Hypersensitivity Reactions to Var-
ied Allergens: Although postmarketing surveillance data are
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scarce, exacerbation of asthma, eczema, and rhinitis was re-
ported shortly after initiation of treatment with immunos-
timulatory drugs (Bini and Weinshel, 1999). The most com-
pelling evidence that immunostim-ulation may be associated
with more frequent hypersensitivity to varied allergens is the
increased incidence of adverse reactions to radiological con-
trast media in patients treated with rIL-2 (Schulman et al.,
1993).
4. Inhibition of Drug-Metabolizing Enzymes: This condition
was evidenced in both animals and man following the
administration of interferon or interferon-inducing agents
(Descotes, 1985). In some instances, this inhibition led to a
clinically significant drug interaction. It has long been recog-
nized that viral infections and inflammation exert similar ef-
fects (Renton, 2001). Cytokines, including rIL-1α and rIL-2,
have been shown to depress hepatic microsomal CYP450-
mediated metabolism after in vitro or in vivo administration
to rodents, and in several instances in man as well.
Hypersensitivity
Hypersensitivity reactions are by far the most frequently re-
ported immunotoxic effects of drugs and other chemicals in
human beings. There are surprisingly few data on the actual inci-
dence of hypersensitivity reactions in the general population or
selected groups of the population. Demoly and Bousquet (2001)
concluded that approximately one-third of all drug-induced ad-
verse reactions consists of hypersensitivity reactions, either im-
munoallergic or pseudoallergic. The skin is the first site of hy-
persensitivity reactions at the workplace followed by the lung.
Around 12% of all allergic contact dermatitis is deemed to be
occupationally related (Rietschel et al., 2002). In the United
States, 10–25% of all asthmas are suggested to be work-related
(Petsonk, 2002). The environment, including indoor air pollu-
tants, is a contributing factor to the development of hypersensi-
tivity reactions and medical allergies, but its impact still remains
to be quantified.
Hypersensitivity reactions can affect nearly every organ or
tissue of the body, although one organ or tissue is often a pre-
dominant target. There are examples, however, of hypersensitiv-
ity reactions that consist of a variety of clinical signs and symp-
toms with no overtly predominant target, such as the multiple
chemical sensitivity syndromes (Bolt and Kiesswetter, 2002).
Underlying mechanisms are not fully elucidated. They consist of
immune-mediated (immuno-allergy) or non-immune-mediated
(pseudoallergy) mechanisms. Because the same mediators, e.g.,
histamine, can be released whatever the mechanism involved,
close similarities in the clinical signs and symptoms are fre-
quently observed (Zuberbier, 1999).
Autoimmunity
Overall, the mechanisms that result in onset and expression
of autoimmunity are largely a mystery. Autoimmune diseases
are relatively common in the general population, although es-
timates vary widely. It is therefore surprising that only a few
epidemi-ological studies have identified drugs or chemicals as a
possible cause of auto-immune disease. Autoimmune diseases
are divided into organ-specific and systemic diseases. Chemi-
cally induced organ-specific diseases are rare, closely similar to
the spontaneous diseases and caused by a very small number
of drugs or chemicals. In contrast, chemically induced systemic
diseases are more frequent, dissimilar from the spontaneous dis-
eases, and caused by various drugs and chemicals (Descotes,
2004b).
EU LEGISLATION
In February 2001, the European Commission published a
white paper on the strategy for a future chemical policy in order
to obtain toxicological information about existing chemicals ac-
cording to Directive 67/548/EEC1. Basic information is lacking
for about 30,000 chemicals produced at quantities of greater
than 1 ton per year, and it is intended that missing data should
be produced without animal experiments where scientifically
satisfactory alternative methods are available. Successful devel-
opment, and validation of test systems can be added to Annex
5 of the Directive 67/548/EEC. The White Paper was discussed
by the Environment Council in June 2001, where it was con-
cluded that “animal testing should be limited to the level nec-
essary to deliver the objectives of the strategy, including a high
level of protection for human health and the environment. Indus-
try should make all existing data available to avoid duplication
of testing. Mechanisms are needed to ensure that unnecessary
testing requirements are avoided. Adequate resources must be
provided for research, development, and validation of globally
accepted test guidelines for alternative in vitro test methods, so
that work can be accelerated at all levels.”
In October 2003, the European Commission adopted a pro-
posal for a new EU regulatory framework for chemicals. Un-
der the proposed new system called REACH (Registration,
Evaluation and Authorisation of CHemicals), enterprises that
manufacture or import more than 1 tonne of a chemical substance
per year would be required to register it in a central database.
The aims of the proposed new regulation are to improve the
protection of human health and the environment while main-
taining the competitiveness and enhancing the innovative capa-
bility of the EU chemicals industry. REACH would furthermore
give greater responsibility to industry to manage the risks from
chemicals and to provide safety information on the substances.
This information would be passed down the chain of produc-
tion. The proposal has been drafted in close consultation with
1Council Directive 67/548/EEC of 27 June 1967 on the approxima-
tion of laws, regulations and administrative provisions relating to the
classification, packaging and labelling of dangerous substances. O.J.
L 196/1 of 16 August 1967. And related Amendments, Adaptations to
Technical Progress, Commission Decisions, and Commission Commu-
nications.
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all interested parties, including via an Internet consultation.2
This has allowed the Commission to propose a streamlined and
cost-effective system. The proposal is now being considered by
the European Parliament and the EU’s Council of Ministers for
adoption.
In the REACH proposal, the repeated dose (28, 90 days)
and chronic (12 months) toxicity test include assessment of im-
munotoxic effects for chemicals produced in quantities of at least
10 tons/year. The method should help to identify chemicals with
immunotoxic potential, which may require further in-depth in-
vestigation of this aspect.
At present, since no alternative methods are available, only
in vivo studies are foreseen. These include:
• morphology/histopathology
• leukocyte counts (flow cytometric analysis)
• serum markers (Ig levels)
These studies are analogous to the ones requested in the OECD
guidelines, in particular number 407 (repeated dose 28-day oral
toxicity),3 408 (repeated dose 90-day oral toxicity),4 and 452
(chronic toxicity).5 Concerning chemicals produced at lower
tonnage (<10 tons/year), there is no existing guideline to eval-
uate immunotoxic effects.
Recent guidelines from the European Medicines Agency
(EMEA)6 emphasize the need to assess immunotoxic effects
during the preclinical phase of drug development, and recom-
mend specific tests to measure immunotoxicity.
U.S. REGULATORY GUIDELINES
In 1997, under U.S. Public Law 103-43, the National Insti-
tute of Environmental Health Sciences (NIEHS) was directed to
develop and validate improved alternative toxicological testing
methods, and to develop criteria and processes for the validation
and regulatory acceptance of such methods. The Interagency Co-
ordinating Committee on the Validation of Alternative Mehods
(ICCVAM) was established as a collaborative effort by NIEHS
and 13 other Federal regulatory agencies and programs for this
purpose. ICCVAM coordinates issues within the U.S. Federal
government that relate to the development, validation, accep-
tance, and national/international harmonization of toxicological
test methods that offer significant advantages over convential an-
imal studies with respect to animal welfare considerations (i.e.,
refinement, reduction, and replacement alternatives). To date,
2〈http://europa.eu.int/comm/enterprise/chemicals/chempol/
whitepaper/consultation.htm〉.
3OECD Guidelines for the Testing of Chemicals, 1997, vol. 1, no. 4,
pp. 1–8.
4OECD Guidelines for the Testing of Chemicals, 1997, vol. 1, no. 4,
pp. 1–10.
5OECD Guidelines for the Testing of Chemicals, 1997, vol. 1, no. 4,
pp. 1–14.
6Note for Guidance on Repeated Dose Toxicity, CPMP/SWP/
1042/99, 〈http://www.emea.eu.int/pdfs/human/swp/104299en.pdf〉.
the only new test method relevant for assessing immunotoxic-
ity to be validated for regulatory purposes through ICCVAM is
the Local Lymph Node Assay (LLNA). The following is a brief
summary of the current recommendations for immunotoxicol-
ogy testing in the United States.
U.S. Food and Drug Administration (FDA). All regulated
products, i.e., small molecular weight drugs,7 biomedical de-
vices,8 and food additives and colorants, should be evaluated
for their potential to produce immunosuppression. With a few
exceptions in the area of hypersensitivity testing, special popula-
tions, and bioengineered food, FDA uses a weight of evidence or
tiered approach to immunotoxicology evaluation of new molec-
ular entities. This is generally accomplished in repeat-dose tox-
icology studies using standard clinical and anatomic pathology
methods. When warranted by observations in general toxicol-
ogy studies, additional studies should be considered to determine
potential effects on immune function. When indicated, immuno-
toxicology tests are expected to be selective and to utilize assays
that are appropriate, technically valid, and predictive. FDA guid-
ance documents are limited to making recommendations and do
not impose requirements on FDA review divisions or regulated
industries.
U.S. Environmental Protection Agency (EPA). The office
of Prevention, Pesticides, and Toxic Substances (OPPTS) has
developed guidelines that are harmonized among the Office of
Pollution, Prevention and Toxics (OPPT), the Office of Pesti-
cide Programs (OPP), and the Organization for Economic Co-
operation and Development (OECD).9 The Health Effects Test
Guidelines are intended to meet testing requirements of both the
Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA)
(7 U.S.C. 136 et seq.) and the Toxic Substances Control Act
(TSCA) (15 U.S.C. 2601).
EPA’s current approach to immunotoxicology evaluation
of chemicals is currently similar to that of the FDA, relying
primarily upon information on potential immunotoxic ef-
fects obtained from hematology, lymphoid organ weights, and
histopathology data from other studies in the database to identify
the need for further testing. EPA has, however, indicated con-
cern regarding the need for more rigorous screening for effects
on immune function both in adults and following development
exposures, in order to provide more accurate information for
risk assessment.
In the absence of relevant in vitro or in vivo models, routine
testing for induction of autoimmune disease is not recommended
at this time by any of the U.S. Federal Agencies discussed here.
7CDER Guidance for Industry: Immunotoxicology Evaluation
of Investigational New Drugs, October 2002 〈http://www.fda.gov/
cder.guidance/4945fnl.doc〉
8CDRH Guidance for Industry and FDA Reviewers—
Immunotoxicity testing Guidance, May 1999 〈http://www.fda.gov/
cdrh/ost/ostggp/immunotox.html〉
9Health Effects Test Guidelines (ftp:fedbbs.access.gpo.gov (IP
162.140.64.19).OPPTS 870.7800 Immunotoxicity. OPPTS 870.2600
Skin Sensitization.
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ANIMAL MODELS
Naturally, the process of risk assessment would be greatly fa-
cilitated if it were based on clinically relevant human data. Such
data are scarce and have been often characterized to be very lim-
ited in scope (Tryphonas and Feeley, 2001). Consequently, much
of the immunotoxicity data used for risk assessment purposes
are generated in experimental animal models. However, scien-
tists working in the field of immunotoxicology continue to be
faced with the question of what species of experimental animal
is most appropriate for immunotoxicity studies. Although there
does not seem to be a satisfactory answer to this question, many
of the early immunotoxicity studies have been performed in ro-
dents since reagents were more readily available for rodents as
compared to those for other species. For information pertaining
to other species, readers are referred to the recent publication by
Helm (2005).
Mice
Initially, there was considerable effort in the development
and validation of a number of immune-related tests in mice.
As these efforts progressed, determination of the robustness of
such tests became an important and necessary issue. The most
comprehensive effort in this area is represented by the work car-
ried out by Luster and collaborators, under the auspices of the
U.S. National Toxicology Program (NTP) (Luster et al., 1992).
In the NTP program, experimental data were collected over the
preceding 10 years on chemicals and therapeutics that were char-
acterized as having the potential to suppress the immune system
and alter host resistance. Data from these studies encompassing
over 50 compounds were analyzed for their likelihood to accu-
rately identify immunotoxic compounds. In addition, tests that
showed significant correlations with data derived from host re-
sistance assays were also identified. Tests that showed the high-
est association with immunotoxicity included the splenic anti-
body plaque forming cell (PFC) response (78% concordance)
and cell surface marker analysis (83% concordance). While a
good correlation was detected between changes in the immune
tests and altered host resistance (e.g., 70% for the antibody PFC
assay, 73% for natural killer (NK) cell activity, and 82% for the
DTH response), no single test could be identified which was
fully predictive for altered host resistance (Luster et al., 1992,
1993). Several of the tests included in this analysis particularly
the lymphoproliferative response to lipopolysaccharide (a B-cell
mitogen) and routine leukocyte counts, were poor indicators for
host resistance changes (<50%). The 1998 U.S. EPA OPPTS
870–7800 Immunotoxicity Guidelines were in fact based on re-
sults of the NTP data analyses. The proposed tests in this guide-
line are limited to the T-dependent antibody PFC assay, the NK
cell function assay, and the quantification of T- and B-cells along
with the suggestion that each chemical be examined and the use
of additional tests be determined on a case by case basis.
Rats
Due to the lower availability of rat-specific reagents, develop-
ment of immunotoxicity tests in this species evolved at a much
slower pace relative to mice. However, since the rat has been
traditionally the experimental model of choice for toxicologic
studies of chemicals, the development of immunologic assays in
rats was imperative. The pioneering work carried out at the Dutch
National Institute of Public Health and the Environment (RIVM)
focused exclusively on the rat (Vos, 1980; Van Loveren and Vos,
1989, 1992; Vos and Van Loveren, 1994). These studies were in-
strumental in formulating the OECD Guideline for the testing of
chemicals: repeated dose 28-day oral toxicity study in rodents,
which was adopted by the Council on 27th July 1995. The 1995
OECD Guideline #407 included histopathologic evaluation of
haematoxylin-eosin stained, paraffin-embedded slides of spleen,
thymus, small intestine, large intestine, and lymph node sections.
Recently, the international collaborative immunotoxicity stud-
ies (ICICIS)10 have been instrumental in revising the OECD
Guideline #407 and to propose changes in the OECD Guide-
line #407, to include in addition to enhanced histopathology of
the immune system, a functional assay preferably one that in-
volves immunization with a foreign antigen. Discussions of the
proposed changes to the OECD guideline #407 are ongoing.
IMMUNE PARAMETERS
Immunohistopathology
A comprehensive investigation of potential chemical-induced
adverse effects on the immune system combines a detailed anal-
ysis of histological examination of key tissues of the immune
system and selected quantitative and functional assays. With re-
spect to pathology, the 1995 OECD guideline #407 requires that
histopathologic evaluation be carried out on the spleen, thymus,
small intestine, large intestine, and lymph node sections. For fur-
ther details regarding the methods and approaches to carry out a
histopathologic evaluation of the tissues of the immune system,
Readers are referred to the publication by Pulido et al. (2005).
Total White Blood Cell Counts
Quantitative and morphologic evaluations of total white
blood cells (WBCs) and differential counts of peripheral blood
leukocytes (PBL) are basic investigations and these have been
included in most immunotoxicity studies involving mice, rats,
and nonhuman primates. Both relative and absolute numbers of
WBCs are quantified. However, absolute numbers provide bio-
logically more relevant information, as the use of percentages
of cell types may mask some cytopenias or excessive numbers
of a cell type, which would lead to falsely high/low numbers of
a particular cell (Perkins, 1999).
Immunophenotyping of Peripheral Blood Leukocytes
Immunophenotyping of PBL, using monoclonal antibodies
directed to cell-surface markers, and flow cytometric techniques,
has become an important tool in the diagnosis of haematologic
10ICICIS, Report of Validation Study of Assessment of Direct Im-
munotoxicity in the Rat. Toxicology, 125, 183, 1998.
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and immunologic disorders (Perkins, 1999). Cross-reactivity be-
tween mouse anti-human monoclonal antibodies (mAbs) and
monkey leukocyte surface antigens has been demonstrated for
several anti human mAbs (Tryphonas et al., 1996). Valuable data
can be gained from repeated measures of lymphocyte subpopu-
lations during the course of a study. Such data can be useful in
elucidating the mode of action of the chemical in question.
Quantification of Total Serum Immunoglobulin Levels
Total serum immunoglobulin (Ig) levels (IgG, IgM, and IgA)
can be quantified in rodents (Bondy and Pestka, 1991) and in
nonhuman primates (Tryphonas, 2005) using the enzyme-linked
immunosorbent assay (ELISA). However, the determination of
total serum Ig levels in experimental animals has not proven
useful, since pronounced effects on immune function are re-
quired before significant changes in total serum Ig levels can be
observed.
Challenge with Specific Antigen
The immune system is endowed with a large functional re-
dundancy and the changes in WBC numbers or shifts in lym-
phocyte subsets observed in many studies may not be accompa-
nied by changes in immune function (Luster et al., 1992). Thus,
the functional capacity of the immune system must be estab-
lished before concluding that a given exposure is toxic. This
can be accomplished by challenging the control and treated an-
imals with foreign antigens, followed by the determination of
antigen-specific antibody levels in serum samples collected prior
to antigenic challenge (baseline titres) and in the case of non-
human primates, at weekly intervals post-immunization. Unlike
total serum immunoglobulins and T-lymphocyte subsets that are
determined sequentially, the challenge with foreign antigens is
performed once during or at the end of treatment. In rodents and
nonhuman primates, challenge with specific antigens has been
highly predictive of effects on humoral immunity (Luster et al.,
1992, 1993; Tryphonas, 2005).
The response to an antigenic challenge involves the sequen-
tial and tightly orchestrated interactions of competent immune
cells, including the antigen-presenting cells, and the activated T-
and B-lymphocytes. Consequently, much information can be de-
rived from challenging the host with foreign antigens. Clinically-
relevant information includes the ability of the host to respond
to a foreign antigen (primary response) and to establish memory
(secondary or anamnestic) response.
For an antigenic challenge to be meaningful, it is important
to have documented histories of the experimental animals, espe-
cially monkeys, since prior immunization can lead to erroneous
results and should be avoided. In rodents, sheep red blood cells
(SRBC) antigens are routinely used for immunization and the
SRBC antibody response is determined by the PFC or plasma
SRBC-specific titer (Jerne et al., 1974). As an alternative for
using SRBC, keyhole limpet hymocyanin (KLH) is considered
as a more stable and robust T-cell-dependent antigen in immu-
nization models. Furthermore, detection of responses to KLH
are better standardized and do not require ex vivo manipulation
(Gore et al., 2004). In non-human primates, SRBC, tetanus tox-
oid (TT) and pneumococcus (Pneu) antigens have been used. In
view of the observed differences in immunogenicity among dif-
ferent batches of SRBC, it is advisable to use the same source of
SRBC for immunization and for the antibody detection systems
for the duration of the study.
Cell-Mediated Immunity
Cell-mediated immunity (CMI) has been studied in rodents
and nonhuman primates using three methods: lymphocyte trans-
formation (LT; 3H-thymidine incorporation) in response to the
T-cell mitogens phytohemagglutinin (PHA) and concanavalin
A (Con A) and the B-plus T-cell activator pokeweed mitogen
(PWM), or to specific antigens such as TT; the mixed lym-
phocyte culture (MLC) assay using allogeneic cells; and the
DTH response using dinitrochlorobenzene (DNCB) (Bugelski
et al., 1990) or oxazolone as the sensitizing agent (Tryphonas,
2005). The LT and MLC assays can be run concurrently and
are followed by the DTH assay. Of these assays, the LT as-
say used in the context of immunotoxicity has provided useful
information regarding the mechanism of action for some chemi-
cals but its predictive value for immune functional impairment is
low (Luster et al., 1992). A potentially useful extension of the LT
assay is the quantitative analysis of Igs in culture supernatants
but this needs further validation. The MLC assay, although a po-
tentially useful assay for predicting chemical-induced adverse
immune effects, has not been standardized and validated across
laboratories and its concordance with host resistance assays or
its predictive value for immune effects is presently not known
(Tryphonas, 2005).
Natural Killer Cell Activity
A number of cells, including cytotoxic T lymphocytes (CTL),
NK cells, and mononuclear phagocytic cells, are endowed with
cytotoxic abilities and are thus very efficient in immunosurveil-
lance mechanisms against neoplastic cells and viral infections.
In immune-compromised hosts, a correlation has been observed
between low NK cell activity and morbidity (Trinchieri, 1989;
Whiteside and Herberman, 1989; Levy et al., 1991) or the in-
cidence and severity of upper respiratory infections (Whiteside
and Herberman, 1989). NK cell function is measured in a 4-hour
51chromium (51Cr)-release assay. In this assay, freshly-isolated
PBL (effector cells) from which monocytes have been removed
by adherence to plastic culture flasks, and 51Cr-labeled K562
target cells (primates) or YAC-1 target cells (rodents) are co-
cultured, and the release of label in culture supernatants is
quantified. In addition, NK cells produce numerous cytokines
such as tumour necrosis factors α and β, interferons α, β,
and γ , granulocyte-macrophage colony-stimulating factor, and
interleukin-3 (IL-3) upon immune stimulation, all of which have
a profound effect on immune reactivity (Trinchieri, 1989).
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Phagocytosis
In addition to their cytotoxic properties, the monocyte/
macrophage lineage of cells is important in antigen recogni-
tion, processing, and presentation to T-lymphocytes. These cells
are potential targets for chemical-induced immunotoxicity and
assays to study functional aspects should be included in the ex-
perimental design.
Various assays have been used in experimental animal mod-
els. Peripheral blood monocytes or peritoneal macrophages have
been used as the source of phagocytic cells. SRBC or latex par-
ticles are commonly used for the ingesting agents. Flow cyto-
metric techniques are available for quantifying the phagocytic
response of cells (Brousseau et al., 1998). However, none of
these assays or techniques has undergone validation and their
predictive value is presently unknown.
Host Resistance Assays
Several host resistance assays have been developed for use
in mice and rats. The use of HR assays gives the experimenter a
valuable tool to determine the host’s immune redundancy. Sev-
eral models of infectivity have been developed (Van Loveren,
1995). These include the models of Listeria monocytogenes,
Streptococcus pneumoniae, Cytomegalovirus, Influenza virus,
Trichinella spiralis, Plasmodium, etc. It should be noted that the
immune defence mechanisms that are operational in combating
infection are different for each of the infectivity models. This ne-
cessitates the use of more than one infectivity model in any given
immunotoxicity study. The choice of the host resistance model
should also take into account the immune parameter affected.
Hypersensitivity and Autoimmunity
The ability to determine the potential for substances (proteins
or chemicals) to cause IgE-mediated hypersensitivity reactions
has been a difficult task for researchers. This applies to a num-
ber of these allergies, including respiratory and food allergies.
Animal models have been used for years to enhance our under-
standing of basic mechanisms of IgE allergic antibody-mediated
disease. For food allergy, animal models presently under de-
velopment include Brown Norway rat, but also a number of
mouse models, including the oral C3H/HeJ and models involv-
ing intraperitoneal administration of proteins (such as BALB/c)
(Knippels and Penninks, 2003). Nonmurine animal models such
as the atopic dog model and the neonatal swine model are
presently under development and have produced promising re-
sults (Helm, 2005).
It is even more difficult to assess immunostimulatory poten-
tial of substances, in particular autoimmunity in animals, mainly
because of the complex etiology of the adverse reactions. There
are only a few individual models that show such immune re-
sponses (Shenton et al., 2004) but none of these seems to be suit-
able as predictive test. The popliteal lymph node assay (PLNA),
in particular combined with immunological read-out parame-
ters (such as response to reporter antigens), is possibly useful as
a screening assay for immunostimulatory hazard of substances
(Pieters et al., 2002). However this assay, which detects lymph
node stimulation upon footpad injection, is not validated, and
uses an obviously irrelevant exposure route. In addition, be-
cause immunostimulation not necessarily leads to autoimmune
derangements, the assay does also not predict whether a chem-
ical really induces such derangements.
Other Parameters
Other assays that measure serum complement levels and cy-
tokine levels (both basal levels and levels in lectin-activated
cultures) are useful parameters in the interpretation of immuno-
logic data. To exclude the possibility that the observed effects on
the immune system are not the result of an indirect effect on hor-
mone levels, investigators have consistently determined serum
levels of cortisol or corticosterone prior to and at the termination
of the study. Due to the effect of stress and the observed diurnal
variation of corticosteroids, the collection of serum specimens
need to be carried out by adhering to a strict randomized order of
all animals in the study for each blood collection (Tryphonas and
Feeley, 2001). The use of carbon dioxide to quickly anesthetize
the animals before bleeding for corticosteroid determination has
been described in mice (Shipp and Woodward, 1998). How-
ever, this should be always combined with a daily randomization
schedule for the order of bleeding.
IN VITRO IMMUNOTOXICOLOGY
Although evaluation of immune function following in vivo
exposure to a test material is arguably the most relevant situation,
it is increasingly desirable to limit the use of animals whenever
possible. Moreover, there are certain situations (for example,
when a test material is anticipated to be dangerous to handle
or is prohibitively expensive) when a totally in vitro system
would be advantageous. Many of the techniques that serve as
the in vitro portion of ex vivo immunotoxicology testing can
serve as stand-alone assessments in a totally in vitro test system
(House, 2001a).
A Workshop on “Immunotoxicology and in vitro possibili-
ties” was organized in 1994, during which the current status of in
vitro methods for assessing immunotoxicity was reviewed and
the possible future developments to reduce, refine, and replace
the use of animals have been analysed (Sundwall et al., 1994).
At that time, experts agreed that there was not an immediate op-
portunity to replace the whole animal for immunotoxicological
studies. On the other hand, much progress has been achieved
regarding the reduction in the number of animals used, since
in vitro models can be used for prescreening. At present a tiered
approach has been proposed, since useful information can be
obtained from regular 28-day general toxicity tests if increased
attention is paid to the study of the histopathology of a large va-
riety of lymphoid tissues, coupled with immunohistochemical
measurements and the determination of classes of antibodies.
Furthermore, it was established that the validation of the in vitro
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test should be against information gained from humans, rather
than the results from laboratory animal species.
In this section we will discuss these assays in the context of
immunosuppression (and, to a lesser degree, its obverse condi-
tion of immunostimulation) and hypersensitivity.
Approaches to Evaluation of Immunosuppression
Initial Evaluation of Myelotoxicity. Compounds that are ca-
pable of damaging or destroying the bone marrow will often
have a profoundly immunotoxic effect, since the effectors of
the immune system itself will not longer be available. Thus, if
a compound is myelotoxic, there may be no need to proceed
with additional evaluation since the material will be a de facto
immunotoxicant. The methodology for evaluating myelotoxicity
in vitro using bone marrow culture systems is well-characterized
(Pessina et al., 2001).
Determination of Lymphotoxicity. Compounds that are not
overtly myelotoxic may still selectively damage or destroy lym-
phocytes, which are the primary effectors and regulators of ac-
quired immunity. This toxicity may result from the destruction
of rapidly dividing cells by necrosis or apoptosis. Viability of the
lymphocytes should be the necessary initial test, and a variety
of methodologies are available for this purpose (e.g., colori-
metric, flow cytometric assays). If the cells are viable (80% or
greater), basic functionality could be determined by performing
an antigen nonspecific proliferation assay. For T-cells, the stim-
ulatory agent can be a combination of anti-CD3 and anti-CD28;
for B-cells an optimum system would have to be developed but
would be expected to be similar to the murine system incorpo-
rating a combination of anti-immunoglobulin and cytokine.
If in vitro systems are found to be useful for assessing
lymphotoxicity, this determination may require broadening to
include other types of immunocytes such as phagocytes. A po-
tential disadvantage of this approach includes the currently un-
determined reliability/reproducibility of this approach, and the
concomitant need for qualification or prevalidation of the assay.
Nonetheless, these assays have distinct advantages including rel-
atively low cost, a readily available source material, and a high
feasibility due to wealth of published methodology.
Determination of Potential Effects on Antibody
Induction/Production
In animals, production of a T-dependent antibody response
(such as against the T-dependent antigen, SRBC or KLH) is con-
sidered to be the “gold standard.” However, there are currently
no good systems for in vitro antibody production using human
cells. Development of human in vitro systems will require opti-
mization of antigen (preferably using antigen relevant to human
exposure, such as TT), culture conditions, and assay endpoint.
In addition, there is some concern whether a primary immune
response can actually be induced in human PBL. One potential
starting point would be an in vitro immunization culture system
based on the Mishell–Dutton assay (this assay is not considered
optimal for this use due to significant variability in results—and
often a complete lack of success—between laboratories). Due
to the high predictivity of human immunotoxicants provided by
the in vivo antibody induction assay, as well as the possibility
of bridging between in vivo and in vitro potentially afforded by
this assay, it is recommended that development of this in vitro
system be given the highest priority.
Determination of Potential Effects on CTL
CTL are a population of CD8+ lymphocytes characterized
by specific cytotoxicity for target cells in an antigen and MHC
Class I-restricted manner. Although they share common mech-
anisms of cytotoxicity with NK cells, they are a distinct pop-
ulation. CTL are able to destroy a variety of targets, including
tumor cells and virally infected cells. CTL require a sensitiza-
tion period in which CTL precursors undergo proliferation and
differentiation into effector cells. Death of the target cells is
by apoptosis, as observed with NK cells. Assessment of CTL
function may reveal deficits not only in the effector phase of
the immune response, but also functional abnormalities in cel-
lular activation and regulatory pathways, such as interferon-γ
production. Methodology for the induction of cytotoxic cells
was first described by Wundelich and Canty (1970), and is com-
posed of two phases: stimulation of CTL precursors by an inac-
tivated tumor cell line for several days, and then measurement of
cytotoxicity using the same cell line labeled with 51Cr. CTL pre-
cursors can be stimulated from splenocytes when using a rodent
assay, or from peripheral blood lymphocytes when assessing the
effects in humans. The key attribute of the stimulating cells is
that they are allogeneic (at least with regard to MHC). Stim-
ulatory cell lines, such as the P815 murine mastocytoma cell
line for rodent CTL, or the Jurkat leukaemic cell line for human
CTL, are used since they are more convenient than primary al-
logeneic cells (lymphocytes for example). Protocols have been
detailed in previous works (House and Thomas, 1995; Lebrec
et al., 1995).
Determination of Potential Effects on NK Cells
NK cells or large granular lymphocytes are involved in non-
specific immunity and, as such, should be included in any in vitro
immunotoxicology study design. CD3−CD16+CD56+ cells ac-
count for 7–41% of the lymphocytes in human peripheral blood
(absolute counts vary between 130 and 1,000/mm3; Pasqualetti
et al., 2003). They have for a long time been recognized as
exquisitely sensitive to perturbants. Both their numbers and their
functional activity have been studied for a long time by toxicolo-
gists. NK cells are enumerated based on surface markers (mainly
CD56) and their cytotoxic function is usually assayed in vitro us-
ing (51Cr) labeled target cells, classically K562 erythroleukemia
cells. Other functional parameters, such as cytokine production,
can also be evaluated, but require prior purification or testing
with and without NK cell removal (e.g., with anti-asialo-GM1
antibody) (Bohn and Autenrieth, 1996).
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Immunotoxicity testing of new pharmaceuticals now in-
cludes cytotoxic NK cell function as a required parameter in
repeated dose toxicity studies. The classical 51Cr-release assay
is the conventional test for cytotoxicity testing. Recently, a flow-
cytometric cytotoxicity assay especially adapted for regulatory
rat studies in drug development has been presented (Marcusson-
Stahl and Cederbrant, 2003). The proportion or absolute num-
bers of NK cells are modified after in vivo exposure to large
numbers of substances or physical agents (Burns et al., 1994;
Ross et al., 1996; Marcusson-Stahl and Cederbrant, 2003).
As NK cell assays are exquisitely sensitive to modulation
by toxic substances, they are usually included in even the most
limited toxicological evaluations. Since NK cells are among the
first to be affected, it is not surprising that the significance is often
questioned. Indeed, changes in NK activity are not often related
to pathological conditions of the immune system. In contrast,
they have been tentatively associated with various conditions of
unknown etiology (Stewart et al., 2003). NK assays have been
used thoroughly to monitor in vivo exposure. The predictive
potential of such assays after in vitro exposure is the subject of
intensive investigation (Lebrec et al., 1995; Condevaux et al.,
2001).
DESCRIPTION OF SELECTED ENDPOINTS
AND METHODOLOGIES
Flow Cytometry
Flow cytometry has been primarily used for immunofluo-
rescent staining of cell surface molecules to differentiate cell
subsets, to detect changes in the composition of heterogenous
cell populations, and to analyse cell activation. Later, techniques
were devised for intracellular staining of DNA (allowing cell cy-
cle analysis, proliferation and apoptosis studies, detection of cy-
totoxicity); more recently, intracellular proteins were analyzed
allowing quantification of cytokine expression and molecular
signals (e.g., activated Stat). Finally, the same apparatus can be
used for chemical measurements: reagents adsorbed or chemi-
cally coupled to the surface of microspheres to capture analytes
that are subsequently measured by a fluorochrome-conjugated
detection molecule. More recently, such assays have been multi-
plexed, or analyzed in the same vial, by performing each reaction
on a set of microspheres that are dyed to different fluorescent
probes and, therefore, are spectrally distinct.
The quantity/quality of leukocyte-expressed biomarkers (sur-
face or intracellular) varies after exposure to noxious compounds
(Leonardi et al., 2000; Hertz-Picciotto et al., 2002). For instance,
in vitro exposure of B-cells to various toxic agents (dioxins, fu-
rans, PAHs, etc.) results in the alteration of the AhR intracellular
levels and of cell surface markers (such as CD19) (Masten and
Shiverick, 1995).
The cytotoxicity of NK cells can also be monitored by flow
cytometry using the DNA probe propidium iodide; target cells
are thus recognized by labelling with 5-(6)-carboxy-fluorescein
succinimidyl ester (Marcusson-Stahl and Cederbrant, 2003). It
can be predicted that flow cytometry techniques will be as use-
ful for in vitro immunotoxicology as they have been for in vivo
experiments (Holladay and Smith, 1995; Rhile et al., 1996;
Tryphonas et al., 1996; Burchiel et al., 1997; Robinson et al.,
1997; Leonardi et al., 2000; Hertz-Picciotto et al., 2002).
Proliferation and Apoptosis
Cell proliferation and cell death are two closely related, phys-
iologically active phenomena. Dysfunction of either of these
mechanisms may cause dysregulations of cell homeostasis, in-
ducing adverse changes in immune function that may increase
susceptibility to infections and cancer, as well as favouring the
development of autoimmune diseases. On the other end, the ac-
tivation of specific immune responses involves the proliferation
of lymphocytes. Antigen-driven activation and proliferation of
lymphocytes are integral steps to in vivo cell-mediated and hu-
moral immune responses.
The mitogen-stimulated proliferative response widely used
in immunotoxicology and in clinical immunology, is an in vitro
correlate of activation and proliferation of lymphocytes specifi-
cally sensitized by antigen in vivo. In vitro stimulation of lym-
phocyte proliferation is an easy assay, and should be included to
assess immune function in in vitro toxicity testing. Furthermore,
in vitro lymphocyte stimulation or transformation could also
be performed using the whole blood assay. Both plant lectins
(e.g., PHA, Con A, PWM, etc.) as well as LPS, purified protein
derivative of tuberculin (PPD), anti-CD3 and/or anti-CD28 an-
tibodies, etc. can be used to stimulate T- or B-cell proliferation
in whole blood. In vitro antigen-specific and mitogen nonspe-
cific activation of lymphocytes results in myriad biochemical
events, including calcium influx, protein kinase C activation,
and phospholipid synthesis, culminating in DNA synthesis and
cell division (Bauer and Baier, 2002; Flavell et al., 2002). Xeno-
biotics interfering with signal transduction pathways are likely
to alter mitogen-induced lymphocyte proliferation.
While any one of these biochemical events can be used as
markers of lymphocyte activation, DNA synthesis, usually mea-
sured by the incorporation of 3H-thymidine, has been the most
widely used endpoint. As an alternative, flow cytometry can be
used to evaluate proliferation analysing expression of prolifer-
ating cell nuclear antigen. Furthermore, using the whole blood
in combination with flow cytometry leukocyte function, prolif-
eration and expression of surface antigens (e.g., CD14, CD25,
CD95), all of which have a potential role in costimulation, ad-
hesion and apoptosis of the immune cells, can be evaluated si-
multaneously (Barten et al., 2003).
The functionality of the immune system could be thus as-
sessed in vitro using whole blood, which allows the assessment
of lymphocyte proliferative responses, apoptosis, cytokine pro-
duction and NK cell activity. The simple use of whole blood
allows the assessment of the functionality of the immune system
without preparation artefacts, it is time effective and less blood
is required, making it a suitable method for in vitro studies.
Functional in vitro studies of immune responses may be very
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sensitive tools, suitable for revealing dysregulation of immune
homeostasis and early predictors of incipient diseases.
Whole Blood Cytokine Release Assay
Cytokines are released as one of the first steps of immune
response and quantitative alterations can be used as a measure
of immunomodulation. Depending on the type of inflammogen
(stimulus), human blood cells release different cytokine patterns,
originating from several blood cell populations. A plethora of
assay systems are available for measuring cytokines and their
receptors such as ELISA, flow cytometry, and molecular biology
techniques such as PCR (House, 2001b). The technique used is
probably of limited importance, and each method has its own
characteristic profile of advantages and disadvantages.
More importantly, but often overlooked, is the requirement
for a careful determination of which cytokines to be measured
to obtain the most useful information. This is confounded by the
highly pleiotropic and redundant nature of cytokines, in which
a single function may be affected by multiple cytokines simul-
taneously. Certain types of cytokines may be proposed (e.g.,
proinflammatory, immunostimulatory, immunosuppressive). In
addition, the continuing process of cytokine discovery may make
attribution of specific function difficult (such as the similarity in
action between cytokines such as IL-2 and IL-15, or IL-4 and
IL-13). For this reason, it is advisable to include the broadest
panel of cytokines possible in any in vitro system using such
analysis.
At present, only the whole blood assay has been prevalidated
for use in in vitro immunotoxicology (Langezaal et al., 2002).
However, most of the cytokine assessment designs currently in
use for the more standard ex vivo immunotoxicology studies
could be qualified using an approach similar to that used in the
whole blood model. Whole blood cytokine release assays have
been in use for more than 20 years. They offer the advantage of
employing human primary cells in their physiological mixture
and environment with little preparation artefacts and ease of
performance, i.e., a handling of liquids without any sophisticated
cell culture technique. Whole blood cytokine release (or more
general mediator release since eicosanoids (von Aulock et al.,
2003), NO, or degranulation products can be determined using
the same approach) was found to be more homogenous between
different donors than the respective models using isolated cells.
The whole blood assay system has been evaluated in a variety
of systems and the results suggest the validity of this model
for assessing immunotoxicity (Borgermann et al., 2002; House
et al., 2002; Araya et al., 2003; Heagy et al., 2003).
A major concern against whole blood models is the interindi-
vidual variation in leukocyte numbers. In fact, in healthy donors,
the normal range of leukocyte numbers is within a fairly narrow
window—few methods to count and adjust cell numbers in rou-
tine practice are as precise as the latter parameter. Furthermore,
using a differential blood cell count, responses can be normal-
ized to the number of a given leukocyte population in the exper-
iment. The model can be used to monitor immune functions ex
vivo, e.g., of volunteers treated with immunomodulatory agents
(Hartung et al., 1995), of patients exposed to toxins or of pa-
tients in order to characterize the course of disease as well as the
effect of treatment. It has proven to be very advantageous that
the same model can be used in vitro and ex vivo.
Stimulation with LPS leads to the release of interleukin-1β
(IL-1β) by monocytes. Experience with the development of the
whole blood pyrogen test (Hartung et al., 1995, 2001; Fennrich
et al., 1999; Hartung, 2002; Schindler et al., 2002). has shown
that IL-1β, which induces inflammation, fever, and septic shock,
qualifies as an endpoint for monocytes with minor differences
to IL-6 or tumor necrosis factor-alpha (TNFα). It has been pre-
viously shown that employing Staphylococcal entero-toxin B
(SEB) and prolonging the incubation period from 48 to 72 hours,
the whole blood model can be extended to determine also the
release of various lymphokines (Hermann et al., 2003). SEB
is a superantigen that can link specific T-cell receptor Vβ re-
gions of the T-cells to MHC Class II molecules present on APC.
This leads to the activation of both APC and T-cells and to re-
lease of various lymphokines such as IL-2, IL-4, IL-13, and
IFNγ . IL-4 was chosen as the lymphokine read-out, since it is
not produced by monocytes and reflects activation of B-cells by
T-helper 2 cells, thus allowing assessment of the interplay of two
major lymphocyte populations. The recent development of cry-
opreserved human whole blood, which can be used after thawing
without further washing steps (Schindler et al., 2002) overcomes
limitations such as blood availability, risks of infections, or ab-
normal responses. Furthermore, the pooling of donors offers the
opportunity of standardized materials.
In conclusion, whole blood incubations provide the ability to
assess either effects on monocytes or lymphocytes employing
selective stimuli. The model has been shown to reflect several
aspects of immunotoxicity such as immunostimulation, priming
and inhibitory effects. Advantages of such human blood cell-
based in vitro tests include:
• Species differences between humans and animals are
avoided.
• Human primary cells are employed in their physiologi-
cal proportions and environment, avoiding preparation
and cultivation artifacts.
• Culture techniques are extremely simple, e.g., allowing
incubations in thermoblocks.
• Cryopreserved blood overcomes problems of availabil-
ity, standardisation and risks of infection.
• In vitro testing is less expensive and time-consuming
than in vivo testing.
• The same test can be employed ex vivo and in vitro.
• The number of compounds and concentrations tested
can be increased.
• The amount of substance required is dramatically re-
duced, allowing testing at earlier stages of drug devel-
opment.
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• Effects on different blood cell populations can be tested
in a single model.
• Changes of cellular immune response can be quanti-
fied, enabling potency testing.
The very simple model of whole blood cytokine release thus
offers a variety of opportunities to assess immune functions in
a highly standardized manner. The predictive value of these ap-
proaches is currently under investigation.
The goal of an in vitro testing approach is to expand beyond
simple screening to more mechanistic evaluation. Some areas of
investigation that would naturally follow from a demonstration
of overall cytokine modulation (as would be detected in the
whole blood model) might include:
1. At what stage is cytokine production affected (transcription,
transduction, release, etc.)?
2. Is cytokine transcription or production skewed toward a dis-
crete phenotype (TH1 or TH2)? Given the increasing knowl-
edge of the role these phenotypes play in health and pathol-
ogy, such information may be invaluable in determining the
ultimate result of any cytokine dysregulation.
3. Are cytokines overproduced (i.e., inflammation) or underpro-
duced (i.e., immunosuppression) in response to a stimulus?
Is cytokine production induced in the absence of an obvious
stimulus?
4. Are cytokine receptors affected (expression, function)?
Keratinocyte Models for Evaluating Sensitizing Potential
The skin is composed of two layers, namely the epidermis and
the dermis, and rests on the subcutaneous adipose tissue. The
epidermis is a multilayered epithelium composed of different
cell types. Keratinocytes (KC) are the major cell type, and repre-
sent about 95% of the epidermal cell mass. They are responsible
for the biochemical and physical integrity of the skin via their
production of keratin and mucopolysaccharides (Barker et al.,
1991). Langerhans cells (LC) comprise the second most promi-
nent cell type in the skin. LC are bone marrow-derived DC and
represent 2% to 5% of the epidermal population. Melanocytes
form some 3% of the epidermal cells and by generating the pig-
ment melanin they protect the skin against ultraviolet radiation.
Besides its barrier function, the skin has been recognised as an
immunologically active tissue. LC are the principal APC in the
skin (Katz et al., 1979). KC not only represent the first target
for irritants, but may also act to convert nonspecific exogenous
stimuli into the production of cytokines, adhesion molecules,
and chemotactic factors (Barker et al., 1991).
The anatomical location of KC and their significant role in the
development of allergic contact dermatitis (ACD) justifies the
use of these cells to evaluate sensitizing potency in vitro. In prin-
ciple, a test system comprised of KC alone may not be useful
in establishing allergenic potency as these cells lack antigen-
presenting capacity. In the epidermis LC exerts this function.
However, in addition to chemical processing, LC activation re-
quires the binding of cytokines produced by KC as a result of ini-
tial chemical exposure. The irritant capacity of allergens might
present an additional risk factor so that irritant allergens may be
stronger allergens than nonirritant ones (Grabbe et al., 1996). In
that case, evaluating irritant potency of allergenic chemicals may
be helpful to establish their allergenic potency, and the potency
of chemicals to induce cutaneous sensitization may be assessed
as a function of KC cytokine expression.
Cytokine Production by Keratinocytes
KC are involved in both ACD and irritant contact dermati-
tis through the synthesis and release of inflammatory cytokines,
chemokines, and growth factors (Ansel et al., 1990; McKenzie
and Sauder, 1990). KC produce a wide range of cytokines in-
cluding IL-1, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, IL-18, IL-20,
TNFα, and IFN-α, -β, and -γ . Unstimulated KC express and se-
crete low levels of cytokines but also provide a reservoir of pre-
formed (primary) cytokines such as IL-1α, IL-1β, and TNFα. In
response to exogenous stimuli, activated KC can produce vari-
ous inflammatory cytokines. For example, IL-1, IL-6, IL-8, and
TNFα exert proinflammatory activity, while IL-1 is chemotactic
for KC, and IL-6 stimulates KC proliferation. IL-8 and TNFα
are produced in response to external stimuli. KC cytokines are
capable of regulating cytoskeletal proteins that become activated
during inflammation (Komine et al., 2001).
Interleukin-7 is considered to be significant in T-cell traffick-
ing (Wagner et al., 1999), as is IL-15 (Han et al., 1999). IL-10,
IL-12, and IL-18 exert systemic effects, whereas IL-10 may ex-
ert anti-inflammatory effects (Moore et al., 2001). It modulates
the function of splenic APC (Ullrich et al., 1994). Furthermore,
IL-10 partly reversed aberrant KC maturation in psoriatic lesions
and decreased expression of IL-8, its receptor CXCR2 and IL-17
(Reich et al., 2001). IL-10R is down-regulated in psoriasis and
acute atopic eczema (Mu¨schen et al., 1999). IL-12 production
by KC has been observed in ACD (Yawalkar et al., 2000). The
antagonism between IL-10 and IL-12 that is observed in other
cell types is also observed in KC. IL-18 has structural homol-
ogy to IL-1, and similar to IL-1 caspase-1 cleaves IL-18 into
a functional form. Human KC constitutively expresses the un-
processed form of IL-18, but the production of the processed
form is subject to debate (Kim et al., 2000; Mee et al., 2000).
IL-1β, TNFα, or IFNγ did not significantly change IL-18 ex-
pression (Companjen et al., 2000). A similar lack of induction
was observed after treatment with LPS or phorbol myristate ac-
etate (Naik et al., 1999; Mee et al., 2000). Inflammatory and
immunological stimuli induce caspase-1 activity in KC, allow-
ing the cleavage of the unprocessed form of IL-1β into an active
form (Zepter et al., 1997); this process may also be operational
for IL-18 (Yamanaka et al., 2000). Intradermal (ID) injection
of IL-18 induced LC migration to the LN (Cumberbatch et al.,
2001), while ID injection of DNA encoding IL-18 resulted in
a mononuclear cell infiltrate (Kremer et al., 1999). IL-18 is in-
creased in psoriatic skin (Naik et al., 1999; Ohta et al., 2001).
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KC also express the IL-18R, on the same cells that show IL-18
in the cytoplasm, suggesting a paracrine or autocrine function
of IL-18 in KC (Koizumi et al., 2001).
KC are a source of IL-10 family members such as IL-20 and
IL-24. IL-20 has a role in normal KC differentiation, and its
receptor is upregulated in psoriatic KC (Blumberg et al., 2001).
Functional IL-24R are demonstrated on KC (Wang et al., 2002).
Also, chemokines and their receptors play important roles in
KC regulation and inflammation. LARC/CCL20 and its recep-
tor CCR6 are expressed by KC and CCL20 expression is strongly
augmented in the lesional skin of psoriasis patients (Nakayama
et al., 2001). KC produce TARC in the lesional but not the nonle-
sional skin of patients with atopic dermatitis (Vestergaard et al.,
2000). KC-derived ligands for CXCR3 and CCR4, such as IP-10,
MIG, and MDC may be involved in T-cell trafficking (Rottman
et al., 2001). MIP-3α is expressed by KC and may attract LC
precursors (Dieu-Nosjean et al., 2000). CCR10 binds CCL27,
which is constitutively produced by KC and can be induced upon
stimulation with TNFα and IL-1β (Homey et al., 2000). KC in-
fluence immigration of inflammatory cells by the expression of
MCP-1, RANTES, IP-10, and MIG (Goebeler et al., 2001).
Receptors for IL-4, IL-13, and IL-17 are present on KC. IL-4
treatment of KC resulted in KC proliferation and IL-6 produc-
tion (Junghans et al., 1996; Wery et al., 1996). IL-13 treatment
induced in IL-6 production (Derocq et al., 1994; Akaiwa et al.,
2001). Activation of IL-17R modulated IFNγ - and IL-4-induced
activation of KC (Albanesi et al., 2000).
Exposure Effects on KC
The irritants croton oil, phenol, and benzalkonium chloride
and the contact allergen dinitrofluorobenzene (DNFB) induced
the production and intracellular accumulation of IL-1α (Wilmer
et al., 1994). A dose-dependent induction of IL-1α mRNA was
seen after neomycin sulphate treatment, while benzocaine did
not affect and dinitrobenzene sulfonate suppressed IL-1α mRNA
expression (Pastore et al., 1995). In a study using five allergens,
two irritants, and two nonsensitizers, only the contact sensitiz-
ers increased cell-associated IL-1α in a dose-dependent fashion
while both allergens and irritants induced the release of this cy-
tokine. Nonsensitising chemicals had no effect on IL-1α (Corsini
et al., 1998). IL-1α as well as TNFα expression by KC was in-
creased after in vivo application of contact sensitizers and croton
oil but not tolerogens (Haas et al., 1992). Using the murine KC
line HEL-30, the allergenic potency of four compounds was es-
tablished on the basis of intracellular IL-1α and intracellular
IL-18. Ranking of potency was similar for the two cytokines
and similar to the ranking established using the local lymph
node assay (van Och et al., 2005).
The irritants sodium lauryl sulphate (SLS), croton oil, and
phenol, but not the sensitizers DNFB and oxazolone, induced
increased production of IL-8 (Wilmer et al., 1994). In contrast,
others observed IL-8 induction by both sensitizers and irritants
(Mohamadzadeh et al., 1994). The latter finding was, however,
obtained using the HaCaT cell line, that differs from primary
KC with respect to IL-18 production (Ka¨mpfer et al., 2000).
The irritants dimethylsulfoxide (DMSO) and SLS, but also the
contact allergen nickel (Ni), induced TNFα mRNA levels in KC.
DMSO and SLS increased promoter activity while Ni increased
mRNA stability (Lisby et al., 1995). Allergens but not irritants
or tolerogens induced IL-12 (Muller et al., 1994; Corsini et al.,
1999). Trinitrobenzene sulphonic acid induced the expression of
CD40 on KC, whereas SLS did not (Coutant et al., 1999). CD80
transcription and cell surface expression on KC were upregu-
lated to similar extents by treatment with allergens or irritants
(Wakem et al., 2000). Finally, CD1d was upregulated in pso-
riasis plaques and by the contact sensitizer poison ivy (Bonish
et al., 2000). CD40, CD54, and HLA-DR expression on KC was
reduced in psoriasis biopsies (Abrams et al., 2000).
DC Models in Hypersensitivity
DC were first identified in the epidermis in 1868 and were
originally known as LC. Their presence in other tissues was
identified in 1973 (Steinman and Cohn, 1973), and DC are now
recognized as an integral part of the immune system. Current
information from humans and mice does not support a conclu-
sive definition of the physiological differentiation pathways that
generate DC in vivo. However, they appear to comprise at least
three distinct subsets, including two within the myeloid lineage,
LC and interstitial DC, and one within the lymphoid lineage, the
so-called lymphoid DC subset also named plasmacytoid DC.
T-Cell immunity against tumors and bacterial or viral infec-
tions relies on the recognition of antigenic peptides processed
and presented to T-cells by APC. During in vivo immune re-
sponses, the role of APC is played primarily by DC acting as
initiators, stimulators, and regulators of antigen-specific T-cells.
Thus, DC form a sentinel network able to detect, capture, and
process antigens such as invading bacteria, viruses, products of
tissue damage and haptens (Aiba et al., 1997; Hacker et al., 1998;
Cella et al., 1999). In peripheral tissues such as the skin, the DC
can be found in contact with KC in an immature state with a
high capacity for antigen uptake and processing but unable to
stimulate T-cells (Cella et al., 1997; Hart, 1997; Banchereau
and Steinman, 1998). Upon antigen capture, stimulation by mi-
crobial products but also in response to inflammatory cytokines
(e.g., TNFα, IL-1) or T-cell-derived signals such as CD40 ligand,
the DC undergo a maturation process leading to the upregula-
tion of co-stimulatory molecules, (CD86, CD80, CD40), MHC
Class II molecules, and the CD83 protein (Caux et al., 1994).
Thereafter, DC migrate to the T-cell areas of lymphoid organs
where they lose antigen-processing activity and become potent
immunostimulatory cells. These maturing DC acquire the abil-
ity to migrate through expression of chemokines and chemokine
receptors and down-regulation of molecules such as E-cadherin.
Indeed, upon maturation DC express a novel chemokine recep-
tor, CCR7, enabling them to migrate in response to gradients of
chemokines (CCL21 and then CCL19) (Yanagihara et al., 1998;
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Gunn et al., 1999; Saeki et al., 1999). Expression of CCR7 is par-
ticularly important, as CCR7-deficient mice show an impaired
migration of activated LC into draining lymph nodes after skin
painting with FITC and consequently, lack any contact hyper-
sensitivity (Forster et al., 1999).
Knowledge of DC physiology has progressed considerably
because of the discovery of culture techniques, in the early
1990s, which support the in vitro generation of large num-
bers of DC from hematopoietic progenitors (Caux et al., 1992).
Two main protocols to generate DC, from either monocytes or
CD34+ hematopoietic cell precursors (HPC), have been de-
scribed. CD34+ HPC, isolated from cord blood or bone mar-
row mononuclear cells, can be induced to proliferate in vitro in
response to several cytokines in combination. TNFα enhances
significantly the proliferation of CD34+ HPC induced by either
IL-3 or GM-CSF. Addition of stem cell factor (SCF) or Flt-3L
(fms-like tyrosine kinase-3 ligand) increases the yield of DC
but does not affect DC differentiation. Many candidate DC are
CD1+ CD14− during the later stages of culture (days 12–14)
from CD34+ HPC in FBS-containing medium. However, when
examined earlier, two DC subsets emerge independently by days
5–7, as defined by the mutually exclusive expression of CD1a
and CD14. When cultured with GM-CSF and TNFα, CD14+
CD1a− intermediates generated E-cadherin−, langerin− CD1a+
interstitial DC that lack Birbeck granules and CD14− CD1a+
intermediates generated E-cadherin+ langerin+ CD1a+ LC-like
DC possessing Birbeck granules by a transforming growth factor
(TGF)-β-independent pathway.
Peripheral blood monocytes cultured with GM-CSF and IL-4
generate immature DC that can be driven into a mature state by
TNFα. Addition of TGFβ to culture of monocytes with GM-
CSF and IL-4 has been shown to induce the differentiation of
peripheral blood monocytes in LC (Geissmann et al., 1998). Ap-
plication of low-molecular-weight chemicals (haptens) to the
skin may result in allergic contact hypersensitivity (Grabbe and
Schwarz, 1998). In vivo painting of murine skin with chemicals,
such as FITC, provokes an influx of epidermal DC in the drain-
ing lymph nodes 24 hours after hapten application (Hill et al.,
1990). These epidermal DC, termed LC, express MHC Class II
molecules and co-stimulatory molecules such as CD86 (Aiba
and Katz, 1990; Kripke et al., 1990). In animal models, produc-
tion of pro-inflammatory cytokines such as IL-1 and TNFα has
been shown to play a major role in DC activation and migration
in contact hypersensitivity (Enk and Katz, 1992; Cumberbatch
et al., 1997). These observations could also be extrapolated to
respiratory sensitization in response to haptens although clear
data in a relevant model have not been established yet. Thus, it
seems that considering similarities between immunity to sim-
ple chemicals and that to infectious agents, it is reasonable to
speculate that hapten itself stimulates DC maturation.
DC are a minor population within epithelial cells in organs
such as epidermal cells in the skin; isolation of this popula-
tion in sufficient numbers is a difficult task and often results in
nonspecific activation of DC. Generating DC from murine bone
marrow CD34+ HPC has been used as an alternative, but this
procedure is time-consuming and requires a significant number
of animals. The establishment of human in vitro models of DC
offered the possibility to demonstrate that haptens were able
to directly activate cultured DC derived from peripheral blood
monocytes or from CD34+ HPC (Aiba et al., 1997; Degwert,
1997; Rougier et al., 2000; De Smedt et al., 2001; Weigt et al.,
2004). Several studies confirmed these observations showing
the up-regulation of maturation markers (CD83, CD80, CD86,
CD40) on human DC (Coutant et al., 1999; Aiba et al., 2000;
Tuschl et al., 2000; Arrighi et al., 2001). Cytokine production
such as IL-12p40, TNFα, and IL-1β has also been reported
upon hapten stimulation (Aiba et al., 1997, 2003; De Smedt
et al., 2001). However, significant differences exist between ex-
perimental systems and authors concerning cytokine production.
Haptenized DC also cause T-cell proliferation in the allogeneic
MLC (Rougier et al., 2000; De Smedt et al, 2001) but not in
the autologous MLC (De Smedt et al., 2001). Recently, the ex-
pression of CCR7 mRNA in human DC stimulated by haptens
and the migration of these cells in response to CCL19 has been
observed (Aiba et al., 2000; Boisle`ve et al, 2004). Boisle`veet al.
(2004) have also documented the presence of CD83+ CCR7+
DC in response to Ni and DNCB.
Mitogen-activated protein kinase (MAPK) has been de-
scribed to play a major role in DC maturation induced by LPS
through Toll-like receptors (Rescigno et al., 1998; Ardeshna
et al., 2000; Underhill and Ozinsky, 2002) or by inflammatory
cytokines through binding to specific receptors (Wajant et al.,
2003). Haptens such as Ni (NiCl2 and NiSO4), DNCB and 2,4-
DNFB induce the phosphorylation of p38 MAPK and c-Jun
N-terminal kinase (JNK). Inhibition of p38 MAPK is correlated
with alteration in phenotypic indicators of maturation such as
CD86, HLA-DR or CD83 in DC derived from monocytes or
from CD34+ HPC stimulated with Ni or DNCB (Arrighi et al.,
2001; Aiba et al., 2003; Boisle`ve et al., 2004).
Mast Cells
Mast cell precursors originate from the bone marrow and
upon migration into different tissues develop into either con-
nective tissue type mast cells (in skin, peritoneum, and lungs) or
mucosal type mast cells (in gastrointestinal tract) (Prussin and
Metcalfe, 2003). The related but functionally slightly different
population of basophils does not reside in tissues but circulates
in the blood where it constitutes 1% of all PBL (Abraham and
Arock, 1998).
Because mast cells bind IgE with high affinity they are gen-
erally considered to be critical effector cells in Type 1 or im-
mediate type hypersensitivity responses (Prussin et al., 2003).
Through crosslinking of membrane-bound IgE by the relevant
antigen, mast cells are induced to secrete the content of their
granules. But mast cells also express Fcγ RIII-IgG and IgG may
be as effective as IgE in triggering mast cell degranulation (Strait
et al., 2002). The released mast cell mediators (e.g., histamine,
serotonin, leukotrienes, prostaglandins, and various proteases
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such as tryptase) induce vascular permeability that facilitates
extravagation of additional leukocytes and inflammatory medi-
ators. In addition, mast cell products induce bronchial constric-
tion and cause other physiological effects related to a Type 1
hypersensitivity response. Because of these effects, mast cells
have a prominent role in airway and food allergy responses, cer-
tain skin diseases such as atopic dermatitis and urticaria, and in
anaphylaxis.
Apart from having an effector function, mast cells are also
involved in the initiation of inflammatory responses. Mast cells
can, for instance, be triggered by complement factors (C3a and
C5a) and endotoxins and are the only cell type capable of storing
presynthesized TNFα, which they can secrete within minutes af-
ter bacterial challenge (McLachlan et al., 2003). Besides TNFα
mast cells produce IL-8 and, as already mentioned, histamine.
Histamine is generally regarded as a mediator of inflammation
and key player in the immediate allergic reaction (MacGlashan,
2003) but histamine has also been demonstrated to have im-
munoregulatory functions. Histamine induces a number of ad-
hesion molecules (E-selectin, ICAM-1 and LFA-1), cytokine
production (proinflammatory cytokines such as IL-1 and IL-6,
but also regulatory cytokines such as IL-10) by various immune
cells. Moreover, histamine has been shown to induce CD86 ex-
pression and chemokine and cytokine production by immature
DC (Caron et al., 2001a, and to promote development of TH2-
stimulating DC (Caron et al., 2001b).
With regard to adaptive immunity, it should be noted that
mast cells express MHC Class I as well as MHC Class II and
various costimulatory molecules (e.g., CD80, CD86, CD40L).
Combined with their capacity to phagocytize diverse particles
and antigens, mast cells may function as APC (Henz et al., 2001).
In addition, mast cells have profound regulatory function on TH1
vs. TH2 responsivenes since they are important sources of IL-4,
IL-5, and IL-13.
Because of the plethora of functions they possess combined
with their strategic tissue localization at borders to the surround-
ing environment, mast cells can be regarded as a crucial cell
type in linking innate with adaptive immunity. In this respect
it is noteworthy that mast cells have been shown to express
various Toll-like receptors (TLR1, TLR2, TLR4, and TLR6),
indicating that mast cells are indeed candidate cells to translate
pathogen-associated molecular signals into an efficient adaptive
immune response (Robbie-Ryan and Brown, 2002; Bellou et al.,
2003).
Not surprisingly, mast cells are found to play a role in many
inflammatory diseases. Apart from allergic diseases they are in-
volved in diseases like irritable bowel syndrome, scleroderma,
rheumatoid arthritis, multiple sclerosis, systemic lupus erythe-
matosus and experimental allergic encephalitis (Robbie-Ryan
and Brown, 2002; Theoharides and Cochrane, 2004).
Finally, mast cells may also play a relevant role in tissue
homeostasis, tissue remodelling, and fibrosis (wound healing),
as well as in processes of tissue angiogenesis (Puxeddu et al.,
2003; Crivellato et al., 2004). Mast cell products also influence
gastrointestinal secretion, absorption, and motility (Siddiqui and
Miner, 2004).
As mentioned, mast cells are important in various aller-
gies, such as airway and food allergy, and possibly also in
various chemically induced autoimmune-like derangements. In
allergy responses mast cell degranulation is immune (i.e., IgE)-
mediated, but mast cells can also be triggered by non-immune-
mediated processes. Apart from complement factors and endo-
toxins, temperature (cold or heat) or exercise may cause mast
cell degranulation without the need for IgE. Also certain drugs
or chemicals can induce non-IgE mediated anaphylaxis. Exam-
ples of such compounds are aspirin and other nonsteroidal anti-
inflammatory drugs, radiocontrast media, opioids, certain mus-
cle relaxants, and HgCl2 (Wu et al., 2001; Kemp and Lockey,
2002; Asero et al., 2003). Also, organic extracts of diesel ex-
haust particles were able to stimulate release of IL-4 and his-
tamine from basophils irrespective of whether they originate
from allergic or nonallergic humans (Devouassoux et al., 2002).
Clearly, mast cells are important from an immunotoxicological
point of view. Therefore, effects on mast cells should be part
of a predictive in vitro panel to assess the immunotoxicological
hazard of chemicals.
Mast cells can be derived from various sources. Human mast
cells in particular can be cultured from CD34+/c-kit+/CD13+
progenitor cells in cord blood by addition of IL-3, IL-6, and
SCF (the ligand for c-kit) (Kirshenbaum et al., 1999). Mouse
or rat mast cells can be generated most efficiently from bone
marrow progenitors in particular in the presence of IL-3, IL-4,
and SCF (Haig et al., 1988; Tsuji et al., 1991). Culture of mast
cells from bone marrow takes 14 to 15 weeks to produce a 99%
pure population. Mast cells can also be isolated from various
tissues (e.g., airways, intestine) or from the peritoneal cavity
(Arock et al., 1989).
Mast cell lines are also available for alternative testing. The
mast cell leukemia HMC-1 cell line has the characteristics of
an immature mast cell that does not express surface FcεRI re-
ceptors but produces histamine and tryptase (Love et al., 1996).
A mast cell line frequently used to assess nonantigen- (Fowler
et al., 2003) or antigen-IgE (Granberg et al., 2001) mediated re-
lease is the rat basophilic leukemia cell line RBL-2H3. This cell
line is often used to determine pharmaceuticals with mast cell
release-inhibiting potential (Granberg et al., 2001). However, the
RBL-2H3 cell line has also been used to determine the effect of
water-soluble cigarette smoke extracts upon mast cell release
(Fowler et al., 2003) or of HgCl2 (Wu et al., 2001). Release of
mast cells can be detected by one or more of its products, for in-
stance mast cell proteases or histamine and mast cell activation
can be detected in many ways, for instance by measurement of
intracellular Ca2+ levels.
SUMMARY
Although the great majority of immunotoxicology data has
heretofore been generated using in vitro systems (with the
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exception of whole-animal host defense models), the testing
approach can more accurately be described as ex vivo in that ex-
posure of the immune system to potential immunotoxicants takes
place in vivo, with subsequent immunological evaluation taking
place in vitro. Although this approach obviates many uncertain-
ties (effect of xenobiotics on primary or secondary lymphoid tis-
sue, potential requirements for metabolism/biotransformation,
etc.), the use of whole animals presents many secondary issues,
such as expense, ethical concerns, and eventual relevance to risk
assessment for humans. The approaches outlined in this review
should provide a first step toward establishing a practical and
predictive in vitro immunotoxicology testing paradigm.
GENERAL RECOMMENDATIONS
• Hypersensitivity and immunosuppression are consid-
ered the primary focus for developing in vitro methods
in immunotoxicology. Nevertheless, in vitro assays to
detect immunostimulation and autoimmunity are also
needed. Although developmental immunotoxicity is an
emerging concern, there are no in vitro test models
available at this time.
• It is recommended to use a flow chart/decision tree
approach to evaluate whether or not a compound is im-
munotoxic (initial screening). Detection of compounds
as potential immunotoxicants can then be followed
up by more detailed in vitro mechanistic assays (e.g.,
antigen-specific or redirected CTL).
• To maximize human relevance, and due to the lack of
species limitations for these assays, it is recommended
that human cells be used for all in vitro test systems.
With the exception of bone marrow assays, the source
of cells should be PBL from donors prescreened for
health, immune reactivity, etc.
• Although the use of primary human cells will be
of the highest clinical relevance, consideration may
eventually be given to the use of sufficiently well-
characterized and validated cell lines (human or
animal) for certain aspects of the test systems. It is
anticipated that most of these assays will be amenable
to a microculture format, increasing efficiency and de-
creasing cost.
• The validation of an in vitro method to detect immuno-
toxicity must depend on high quality in vivo data. It is
essential that a sufficiently large number of positive and
negative reference compounds, including both drugs
and chemicals, be tested. To this aim the establishment
of a human database is strongly recommended. This
could be accomplished by a coordinated effort from
governmental agencies, medical institutions, and in-
dustry. Access to any extensive animal databases, when
available, will also be helpful.
In vitro Testing
Immunosuppression.
• An initial evaluation of myelotoxicity should be per-
formed. If a compound is myelotoxic, there may
be no need to proceed with additional evaluation.
The methodology for bone marrow culture systems
is published and well characterized. In vitro bone
marrow culture systems are commercially available,
and they would probably have to be modified slightly
to accommodate in vitro exposure to test material.
Assays of immunosuppression have been validated
to predict the maximum tolerated dose (MTD) in
humans. Their suitability for use in immunotoxicology
should be determined and would require prevalidation.
These assays are relatively expensive if human cells
are used, and the standardized nature of commercial
systems should provide good feasibility.
• An in vitro test to determine lymphotoxicity should be
carried out (cell death by necrosis or apoptosis). Such
assays would require prevalidation to evaluate their re-
liability/reproducibility. Viability of the lymphocytes
should be the necessary initial test (e.g., colorimet-
ric, flow cytometric assays). If the cells are viable
(perhaps 80% or greater), basic functionality would
be determined by performing an antigen nonspecific
proliferation assay. For T-cells, the stimulatory agent
would be a combination of anti-CD3 and anti-CD28;
for B-cells an optimum system would have to be
developed but would be expected to be similar to the
murine system incorporating an anti-immunoglobulin
and cytokine. This determination may require broad-
ening to include other types of immunocytes (e.g.,
phagocytes). These assays are relatively inexpensive
(source material is readily available); the feasibility is
high due to wealth of published methodology.
• Potential effects on cytokine expression should be de-
termined. The role of cytokine transcription or pro-
duction should be evaluated as well as the modulation
of cytokine receptors. It should also be investigated
if cytokine transcription or production is skewed
(TH1/TH2). It will require careful determination of
which cytokines to measure to obtain most useful in-
formation (e.g., proinflammatory, specific immunoreg-
ulatory cytokines). It is recommended to investigate
a broader panel of cytokines than is currently used.
Both basal and activated cytokine production should
be measured, and for activated cytokine production,
anti-CD3 and anti-CD28, LPS, or allergen should be
used. Whole blood assay is the most promising option
due to advanced stage of prevalidation.
Many other assay systems are available for measur-
ing cytokine expression (e.g., ELISA, flow cytometry,
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molecular biology techniques such as PCR). They are
moderately expensive, and their feasibility is high due
to wealth of published methodology and commercial
standardization.
• Potential effects on NK cells should be determined.
Cytolytic function should be measured (this is im-
portant for innate immunity). There are a variety of
systems available for measuring cytolytic function
(e.g., whole blood, radiolabel release, flow cytometry);
these systems are robust and well characterized. The
immunoregulatory function of NK cells should be
evaluated due to the key regulatory nature of these
cells. At present, such a system is not well described,
and would require method development. A feasible
system would probably be a modification of existing
whole blood model or other cytokine methods. The
systems currently in use are highly reliable and
reproducible; implementation for in vitro exposure
would require additional development. The cost of
performing these assays is dependent on assay end-
point, but overall relatively inexpensive; feasibility is
high due to extensive past usage of this methodology.
In addition, these systems will require prevalidation
for exclusive in vitro exposure.
Hypersensitivity
• Models for antigen-driven hypersensitivity
– It is believed that in this case the hapten will bind
to soluble or cellular proteins leading to uptake
by the DC, processing of the hapten-protein com-
plex and association of processed hapten-peptides
with MHC Class II molecules. DC will then mi-
grate from the point of entry of the hapten to drain-
ing lymph nodes where presentation of the hapten-
peptide complex to naı¨ve T-lymphocytes occurs.
Hapten-specific T-lymphocytes will then proliferate
and differentiate.
– DC play a central role in this mechanism and the use
of in vitro model based on human DC needs to be
encouraged.
– Type of model: DC/CD34+ or Mo-DC (+/-TGFβ)
– Evaluation of different existing protocols for DC
generation is needed (cytokines, serum-free media,
or FBS)
– Protocol standardization of each experimental phase
needs to be performed (timing of treatment, hapten
treatment, etc).
– Parameters to be measured:
• Cytotoxicity: This parameter needs to be care-
fully evaluated, especially the kinetics since
after activation, DC will die upon reaching the
lymph nodes; this type of death needs to be
distinguished from direct toxicity of the tested
molecule.
• Core parameters: CD86, CD83, CCR-7,
ICAM-1, MHC Class II, TNFα, IL-12, IL-10.
• Other parameters: E-cadherin, CCR6, Lan-
gerin, IL-1β, TARC.
– The protocol refinement: After this first step and af-
ter the definitive choice of the model and of the most
appropriate protocol, it will be needed to confirm the
relevance of the observations using a coculture sys-
tem with lymphocytes. This step can be performed
on a small number of relevant haptens with the fol-
lowing primary read-out: proliferation and cytokine
profiling.
• Models for nonantigen-driven activation of the immune
system leading to hypersensitivity reactions
Immunoregulation (Adjuvants, Superantigen).
• It has been shown that lymphocytes can be directly ac-
tivated by microbial products (superantigen concept)
leading to release of cytokines and clinical effects.
To date, there is no example of this type of effect
with low molecular weight chemicals. The existing
whole blood assay should be considered to address this
question.
• Adjuvants may be included in vaccine formulations
to enhance the immune responses to particular anti-
gen(s). It is known that certain compounds can have
adjuvant activity through direct or indirect activation
of DC. Indirect activation can also result from non-
immune cells present at the site of exposure to the
compound.
• For direct activation, human DC models are suitable,
as previously described. For indirect activation the use
of other cell models should be encouraged depending
on the route of exposure e.g., human lung epithelial
cells, human keratinocytes.
• In the case of nonimmune cells we recommend to
evaluate cytotoxicity and proinflammatory mediators
release e.g., cytokines, chemokines.
Mediator Release.
• Compounds may induce the direct release of mediators
e.g., histamine, cytokines, eicosanoids, or the activation
of the complement cascade leading to hypersensitivity
reactions.
• The use of the whole blood assay can address the re-
lease of mediators by basophils (histamine) and mono-
cytes (cytokines).
• The use of mast cell models needs also to be considered.
At the moment, there is no strong evidence for a role of
eosinophils directly activated by compounds. Models
are available.
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Major Limitations and Future Research Needs
• In vitro exposure is most straightforward for direct im-
munotoxicants. However, materials that require bio-
transformation would require special culture systems
(e.g., culture in the presence of S9).
• Physiochemical characteristics of the test material may
interfere with the in vitro system. Such characteristics
may include the need for serum, effects of vehicle on
cells (such as DMSO), and chemical binding to cells. In
order to retain the viability of the cells to an acceptable
level, in vitro exposures are often performed in 0.1%
ethanol or 0.1% DMSO as maximum solvent concen-
tration, thereby maximising the exposure concentra-
tion of the xenobiotic. This is an additional limitation
of in vitro systems.
• In vitro systems do not take into account the interactions
of the different components. It is difficult to reproduce
in vitro the integrity of the immune system.
• In vitro systems do not account for potential neuro-
immuno-endocrine interactions. There is no antici-
pated resolution for this deficiency at present.
• The current state of technology does not allow evalu-
ation of the induction of a memory response in vitro.
Resolution of this deficiency will require the develop-
ment of novel culture systems.
• The current state of technology does not allow eval-
uation of recovery (acute vs. long-term immunosup-
pression). Resolution of this deficiency will require the
development of novel culture systems.
• The current state of technology does not allow for eval-
uation of toxic effects on lymphoid architecture that
could lead to defects in cellular interactions necessary
for induction of immune responses (e.g., lymph nodes).
Future developments in tissue engineering may solve
this problem, but this is a long-range possibility.
• Exclusive use of human cells may limit the ability to
bridge to the preexisting database of animal immuno-
toxicology studies.
• The use of “-omics” should be considered for the search
of new parameters and for the possibility of gene pro-
filing after hapten treatment.
• Determination of potential effects on antibody induc-
tion/production.
• In animals, production of a T-dependent antibody (such
as SRBC) is considered to be the gold standard. How-
ever, there are currently no good systems for in vitro
antibody production using human cells.
• Development of human in vitro systems will require
optimization of stimulator (preferably using antigen
relevant to human exposure, such as TT), culture condi-
tions, and assay endpoint(s). For these reasons, further
research in this area is strongly recommended.
• There is a need for research to develop in vitro models
to detect autoimmunity and immunostimulation.
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